AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11334201 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrox
Number of subjects: 90
Study 11334201 — intervention group
Group type: EXPERIMENTAL
Intervention: Affinity
Number of subjects: 90
Study 11334201 — intervention group
Group type: EXPERIMENTAL
Intervention: Capiox
Number of subjects: 90
Study 11334201 — intervention group
Group type: EXPERIMENTAL
Intervention: Optima
Number of subjects: 90
Study 11334201 — intervention group
Group type: EXPERIMENTAL
Intervention: Hilite
Number of subjects: 90
Study 11334201 — intervention group
Group type: EXPERIMENTAL
Intervention: All oxygenators
Number of subjects: 90
Study 9673431 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 or 5 mg once daily)
Number of subjects: 20
Study 9673431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard (10 or 20 mg twice daily)
Number of subjects: 20
Study 7517477 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 188
Study 7517477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 7517477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined index of pain-free walking distance, maximum walking distance, and pressure indices
Number of subjects: 188
Study 3293372 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus (150 ml or 175 ml depending on weight)
Number of subjects: 90
Study 3293372 — intervention group
Group type: EXPERIMENTAL
Intervention: Split bolus (first bolus 100 or 125 ml, second bolus 50 ml)
Number of subjects: 90
Study 3293372 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-drip (initial bolus 100 or 125 ml followed by rapid IV drip infusion of 50 ml)
Number of subjects: 90
Study 3293372 — intervention group
Group type: COMPARATOR
Intervention: Bolus-drip method
Number of subjects: 90
Study 30260268 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg for 7 days
Number of subjects: 0
Study 30260268 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene counseling
Number of subjects: 0
Study 28292334 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide Cement (CH)
Number of subjects: 27
Study 28292334 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified Glass Ionomer Cement (RMGIC)
Number of subjects: 27
Study 28292334 — intervention group
Group type: COMPARATOR
Intervention: Gutta Percha (Control)
Number of subjects: 27
Study 26289557 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 42
Study 26289557 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional anti-HF therapies)
Number of subjects: 42
Study 23282113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 336
Study 23282113 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 336
Study 21843876 — intervention group
Group type: EXPERIMENTAL
Intervention: argon laser trabeculoplasty (ALT) after topical betaxolol hydrochloride treatment
Number of subjects: 127
Study 21843876 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP before ALT
Number of subjects: 127
Study 21843876 — intervention group
Group type: EXPERIMENTAL
Intervention: treating surgeon
Number of subjects: 127
Study 19515732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet with close supervision by a dietitian and provision of basic foods
Number of subjects: 90
Study 19515732 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean-style diet (control group)
Number of subjects: 90
Study 19515732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet with close supervision
Number of subjects: 90
Study 16377363 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 614
Study 16377363 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder
Number of subjects: 614
Study 16377363 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical heavy drinking
Number of subjects: 614
Study 16377363 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent drinking
Number of subjects: 614
Study 16377363 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence of two or more anxiety and/or mood disorders
Number of subjects: 614
Study 14763921 — intervention group
Group type: EXPERIMENTAL
Intervention: Graves' disease (GD) patients
Number of subjects: 43
Study 14763921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT)
Number of subjects: 43
Study 14763921 — intervention group
Group type: EXPERIMENTAL
Intervention: Graves' disease (GD)
Number of subjects: 43
Study 14763921 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid autonomy (TA)
Number of subjects: 43
Study 11182175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 10 mg once daily
Number of subjects: 378
Study 11182175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg once daily
Number of subjects: 378
Study 11182175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily
Number of subjects: 378
Study 11182175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 378
Study 11182175 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg twice daily
Number of subjects: 378
Study 9156375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic acidic liquid enema (45 micrograms nicotine base/kg)
Number of subjects: 30
Study 9156375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic basic liquid enema (45 micrograms nicotine base/kg)
Number of subjects: 30
Study 9156375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acidic liquid enema (45 micrograms nicotine base/kg)
Number of subjects: 30
Study 9156375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic basic liquid enema (45 micrograms nicotine base/kg)
Number of subjects: 30
Study 9156375 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution (45 micrograms nicotine base/kg)
Number of subjects: 30
Study 9156375 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nicotine (15 micrograms nicotine base/kg)
Number of subjects: 30
Study 8097304 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium bromide (100-150 micrograms/kg)
Number of subjects: 30
Study 2877702 — intervention group
Group type: EXPERIMENTAL
Intervention: d-propranolol
Number of subjects: 36
Study 2877702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31568099 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual perspective-taking intervention
Number of subjects: 436
Study 31568099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 436
Study 29710760 — intervention group
Group type: EXPERIMENTAL
Intervention: Live action observation training (AOT)
Number of subjects: 12
Study 29710760 — intervention group
Group type: COMPARATOR
Intervention: Video action observation training (AOT)
Number of subjects: 12
Study 26374171 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-stabilized anorganic bovine bone (ABBM-C)
Number of subjects: 40
Study 26374171 — intervention group
Group type: COMPARATOR
Intervention: Anorganic bovine bone + autogenous bone (ABBM + AB)
Number of subjects: 40
Study 25145781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Wuzhi capsules (WZC) + corticosteroids
Number of subjects: 60
Study 25145781 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus + corticosteroids
Number of subjects: 60
Study 22205241 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 MBq I‐131 (low dose)
Number of subjects: 108
Study 22205241 — intervention group
Group type: EXPERIMENTAL
Intervention: 3700 MBq I‐131 (high dose)
Number of subjects: 108
Study 21147441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajmaline (1 mg/kg) infused at 1 mg/sec
Number of subjects: 32
Study 21147441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajmaline (1 mg/kg) infused over 10 minutes
Number of subjects: 32
Study 21147441 — intervention group
Group type: COMPARATOR
Intervention: Rapid infusion rate (assessed retrospectively during 386 challenges)
Number of subjects: 32
Study 21147441 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion rate (assessed during the study)
Number of subjects: 32
Study 21147441 — intervention group
Group type: COMPARATOR
Intervention: Rapid infusion rate (assessed during the study)
Number of subjects: 32
Study 18056188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucocorticoid therapy
Number of subjects: 74
Study 16265847 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous axillary brachial plexus block with 10 ml 0.75% ropivacaine loading dose followed by 4-5 ml per hour infusion for up to three days (Group A)
Number of subjects: 18
Study 16265847 — intervention group
Group type: COMPARATOR
Intervention: No continuous analgesia postoperatively (Group B)
Number of subjects: 18
Study 12410195 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Permethrin Creme Rinse (1% PLT) without combing
Number of subjects: 95
Study 12410195 — intervention group
Group type: COMPARATOR
Intervention: 1% Permethrin Creme Rinse (1% PLT) with adjunctive combing
Number of subjects: 95
Study 9857653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) mast cell analysis using Carnoy's solution as a fixative and 0.5% solution of Toluidine blue for staining.
Number of subjects: 38
Study 7837931 — intervention group
Group type: EXPERIMENTAL
Intervention: eptastigmine 12mg tid
Number of subjects: 25
Study 7837931 — intervention group
Group type: EXPERIMENTAL
Intervention: eptastigmine 20mg tid
Number of subjects: 25
Study 7837931 — intervention group
Group type: EXPERIMENTAL
Intervention: eptastigmine 28mg tid
Number of subjects: 25
Study 7837931 — intervention group
Group type: EXPERIMENTAL
Intervention: eptastigmine 48mg tid
Number of subjects: 25
Study 7837931 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 2231482 — intervention group
Group type: COMPARATOR
Intervention: Normal running (control group)
Number of subjects: 40
Study 2231482 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from running (experimental group)
Number of subjects: 40
Study 27539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (30 to 40 mg/day in three divided doses)
Number of subjects: 40
Study 27539 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (15 to 20 mg/day in three divided doses)
Number of subjects: 40
Study 31883327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (4 g dose intravenously 3 hours before catheter placement and removal)
Number of subjects: 82
Study 31883327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 30728754 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 1052
Study 30728754 — intervention group
Group type: COMPARATOR
Intervention: Location of hormone replacement therapy
Number of subjects: 1052
Study 30728754 — intervention group
Group type: COMPARATOR
Intervention: Information received about HRT
Number of subjects: 1052
Study 30728754 — intervention group
Group type: COMPARATOR
Intervention: Physicians' counselling and involvement
Number of subjects: 1052
Study 30728754 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of complications associated with HRT
Number of subjects: 1052
Study 30728754 — intervention group
Group type: COMPARATOR
Intervention: Employment status
Number of subjects: 1052
Study 28887069 — intervention group
Group type: EXPERIMENTAL
Intervention: BREATHE transitional care program
Number of subjects: 240
Study 28887069 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 26255088 — intervention group
Group type: EXPERIMENTAL
Intervention: 2PN Cryo group
Number of subjects: 140
Study 26255088 — intervention group
Group type: COMPARATOR
Intervention: Blast Cryo group
Number of subjects: 140
Study 23337838 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy for 8 months
Number of subjects: 119
Study 21088920 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 2155
Study 21088920 — intervention group
Group type: COMPARATOR
Intervention: White patients
Number of subjects: 2155
Study 19051273 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically significant (CS) change in symptoms of ADHD and ODD
Number of subjects: 0
Study 19051273 — intervention group
Group type: COMPARATOR
Intervention: No clinically significant (CS) change in symptoms of ADHD and ODD
Number of subjects: 0
Study 16678550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg for 2 days, then two 50 mg doses 12 hours apart for 5 days)
Number of subjects: 30
Study 16678550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30
Study 16678550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15361807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 15361807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 15361807 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 15361807 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex and Carbamazepine
Number of subjects: 0
Study 11786648 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG (20 g daily for 12 weeks)
Number of subjects: 27
Study 11786648 — intervention group
Group type: COMPARATOR
Intervention: TAG (20 g daily for 12 weeks)
Number of subjects: 27
Study 9403748 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (28 degrees C)
Number of subjects: 0
Study 9403748 — intervention group
Group type: COMPARATOR
Intervention: Mild hypothermia (34 degrees C)
Number of subjects: 0
Study 8133022 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine taken in the morning
Number of subjects: 20
Study 8133022 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine taken in the evening
Number of subjects: 20
Study 8133022 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurement of blood pressure
Number of subjects: 20
Study 8133022 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-Event-Monitoring System (MEMS)
Number of subjects: 20
Study 8133022 — intervention group
Group type: EXPERIMENTAL
Intervention: Days with missed medication removed from analysis
Number of subjects: 20
Study 3499896 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimotion sickness medications scopolamine:d‐amphetamine (0.4:5.0 mg)
Number of subjects: 0
Study 3499896 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine:ephedrine (25:60 mg)
Number of subjects: 0
Study 3499896 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxyn (275 or 550 mg)
Number of subjects: 0
Study 30950739 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive voice therapy (IVT)
Number of subjects: 46
Study 30950739 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual IVT (IVT-I)
Number of subjects: 46
Study 30950739 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IVT (IVT-G)
Number of subjects: 46
Study 30950739 — intervention group
Group type: COMPARATOR
Intervention: Long-term traditional voice therapy (TVT)
Number of subjects: 46
Study 29395938 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrician-performed comprehensive geriatric care (CGC)
Number of subjects: 368
Study 29395938 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 368
Study 26672793 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention (cognitive behavioural therapy)
Number of subjects: 37
Study 26672793 — intervention group
Group type: COMPARATOR
Intervention: Usual counselling care
Number of subjects: 37
Study 24508419 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) at a fixed dose level of 0.6 U/kg for 6 days
Number of subjects: 59
Study 24508419 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir at a fixed dose level of 0.6 U/kg for 6 days
Number of subjects: 59
Study 22171564 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U/kg rhC1INH
Number of subjects: 0
Study 22171564 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U/kg rhC1INH
Number of subjects: 0
Study 22171564 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 20435375 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge surgical site infections (SSIs)
Number of subjects: 622683
Study 20435375 — intervention group
Group type: COMPARATOR
Intervention: Common risk indices
Number of subjects: 622683
Study 18566798 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching live arthroscopic views (group W)
Number of subjects: 63
Study 18566798 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 63
Study 14759562 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin (AM) concentration in patients with PAOD
Number of subjects: 72
Study 14759562 — intervention group
Group type: COMPARATOR
Intervention: Plasma adrenomedullin (AM) concentration in patients without PAOD
Number of subjects: 72
Study 14759562 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma AM concentration with inflammatory parameters
Number of subjects: 72
Study 14759562 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of mature and intermediate forms of AM
Number of subjects: 72
Study 14759562 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up of mature form of AM from femoral artery to saphenous vein
Number of subjects: 72
Study 11545752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 4159
Study 11545752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study 14655848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Therapy (CBT)
Number of subjects: 51
Study 14655848 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Group Psychoeducation and Fluoxetine (GPF)
Number of subjects: 51
Study 7951808 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade cereal‐based oral rehydration therapy (HC‐ORT, n = 103)
Number of subjects: 291
Study 7951808 — intervention group
Group type: COMPARATOR
Intervention: Glucose‐based oral rehydration solution (G‐ORS, n = 98)
Number of subjects: 291
Study 7951808 — intervention group
Group type: COMPARATOR
Intervention: Cereal‐based oral rehydration solution (C‐ORS, n = 90)
Number of subjects: 291
Study 3311117 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms salbutamol
Number of subjects: 10
Study 3311117 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg salbutamol
Number of subjects: 10
Study 3311117 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg salbutamol
Number of subjects: 10
Study 3311117 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg salbutamol
Number of subjects: 10
Study 3311117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29773484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 8 mg
Number of subjects: 52
Study 29773484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26525425 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study 26525425 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted
Number of subjects: 130
Study 26525425 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 130
Study 26525425 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovered
Number of subjects: 130
Study 23382092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle management and sibutramine
Number of subjects: 61
Study 21682757 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 (sustained-release recombinant growth hormone) for 12 months
Number of subjects: 11
Study 21682757 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months followed by LB03002 for 6 months
Number of subjects: 11
Study 21682757 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 (sustained-release recombinant growth hormone)
Number of subjects: 11
Study 20172051 — intervention group
Group type: EXPERIMENTAL
Intervention: CeO(2) nanoparticles; pretreatment with varying concentrations 24 hours before radiation exposure.
Number of subjects: 0
Study 20172051 — intervention group
Group type: EXPERIMENTAL
Intervention: CeO(2) nanoparticles; intraperitoneal injections before radiation exposure.
Number of subjects: 0
Study 18343738 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy combined with probiotics
Number of subjects: 0
Study 18343738 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 18343738 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative therapeutic options (immunotherapy, ion-exchange resins, new drugs)
Number of subjects: 0
Study 16319952 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (300 mg/m2) + Melphalan (200 mg/m2)
Number of subjects: 49
Study 13678769 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 3204
Study 13678769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3204
Study 11052393 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored sensory and coping information about analgesic side effects
Number of subjects: 43
Study 11052393 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual control group
Number of subjects: 43
Study 8686822 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (first on the operating list)
Number of subjects: 60
Study 8686822 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (4-5 hours later on the operating list)
Number of subjects: 60
Study 1425158 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20
Study 1425158 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 20
Study 2857213 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 630
Study 2857213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study 31468171 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 21
Study 31468171 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment
Number of subjects: 21
Study 31468171 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 21